{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:43:30Z","timestamp":1779889410736,"version":"3.53.1"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:00:00Z","timestamp":1718236800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>Mycophenolate dose reduction (MDR) is associated with acute rejection and transplant failure in kidney transplant recipients (KTRs). The optimal dose to prevent rejection and reduce complications remains poorly defined in tacrolimus-based regimens.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>We assessed adult KTRs from 2005 to 2017 initiated on mycophenolate mofetil 2\u2009g\/d, tacrolimus, and prednisolone from the Australia and New Zealand Dialysis and Transplant Registry. KTRs with rejection within the first 30 d posttransplant were excluded. The primary outcome was time to first rejection between 30 d and 2 y posttransplant. Mycophenolate dose was modeled as a time-varying covariate using Cox proportional hazards regression. Secondary outcomes included assessment of early MDR to &lt;1.5\u2009g\/d within the first 6 mo posttransplant and subsequent patient and death-censored graft survival.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>In the primary analysis, 3590 KTRs were included. Compared with mycophenolate dose of \u22652\u2009g\/d, both 1.0\u2013&lt;1.5 and &lt;1\u2009g\/d were associated with an increased risk of rejection during the 2 y posttransplant (hazard ratio [HR] 1.67; 95% confidence interval [CI], 1.29-2.16; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u20050.001 and HR 2.06; 95% CI, 1.36-3.13; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.001, respectively) but not 1.5\u2013&lt;2\u2009g\/d (HR 1.20; 95% CI, 0.94-1.53; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.14). Early MDR to &lt;1.5\u2009g\/d occurred in 45.3% of KTRs and was an independent risk factor for death-censored graft failure (HR 1.32; 95% CI, 1.05-1.66; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.016) but not death (HR 1.18; 95% CI, 0.97-1.44; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.10), during a median follow-up of 5.0 (interquartile range, 2.6\u20138.5) y.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>Early MDR was a risk factor for subsequent rejection and graft failure in KTRs receiving contemporary tacrolimus-based regimens.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/txd.0000000000001659","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T21:17:41Z","timestamp":1718313461000},"page":"e1659","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Mycophenolate Dose Reduction in Tacrolimus-based Regimens and Long-term Kidney Transplant Outcomes in Australia and New Zealand"],"prefix":"10.1097","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3771-9102","authenticated-orcid":false,"given":"Darren","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Renal Medicine, Eastern Health Clinic School, Monash University, Box Hill, VIC, Australia."},{"name":"Department of Nephrology, Austin Health, Heidelberg, VIC, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevan R.","family":"Polkinghorne","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Monash Health, Clayton, VIC, Australia."},{"name":"Department of Medicine, Monash University, Clayton, VIC, Australia."},{"name":"Department Epidemiology and Preventative Medicine, Monash University, Clayton, VIC, Australia."},{"name":"Department of Medicine, Centre for Inflammatory Diseases, Monash University, Clayton, VIC, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Pilmore","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine, Auckland City Hospital, Auckland, New Zealand."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Mulley","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Monash Health, Clayton, VIC, Australia."},{"name":"Department of Medicine, Centre for Inflammatory Diseases, Monash University, Clayton, VIC, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,6,13]]},"reference":[{"key":"R1-20240805","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation.","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"key":"R2-20240805","article-title":"44th Report, Chapter 7: Kidney Transplantation. Australia and New Zealand Dialysis and Transplant Registry, Adelaide, Australia."},{"key":"R3-20240805","year":"2022","journal-title":"OPTN\/SRTR 2020 Annual Data Report"},{"key":"R4-20240805","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1681\/ASN.2017030287","article-title":"Class II Eplet mismatch modulates tacrolimus trough levels required to prevent donor-specific antibody development.","volume":"28","author":"Wiebe","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"R5-20240805","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/TP.0b013e31817fdddb","article-title":"Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant.","volume":"86","author":"Opelz","year":"2008","journal-title":"Transplantation"},{"key":"R6-20240805","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/01.tp.0000225760.09969.1f","article-title":"Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure.","volume":"82","author":"Bunnapradist","year":"2006","journal-title":"Transplantation"},{"key":"R7-20240805","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1399-0012.2012.01694.x","article-title":"Does reduction in mycophenolic acid dose compromise efficacy regardless of tacrolimus exposure level? An analysis of prospective data from the Mycophenolic Renal Transplant (MORE) Registry.","volume":"27","author":"Langone","year":"2013","journal-title":"Clin Transplant"},{"key":"R8-20240805","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/tri.12133","article-title":"Reasons for dose reduction of mycophenolate mofetil during the first year after renal transplantation and its impact on graft outcome.","volume":"26","author":"Vanhove","year":"2013","journal-title":"Transpl Int"},{"key":"R9-20240805","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1345\/aph.1P456","article-title":"Impact of mycophenolate mofetil dose reduction on allograft outcomes in kidney transplant recipients on tacrolimus-based regimens: a systematic review.","volume":"45","author":"Su","year":"2011","journal-title":"Ann Pharmacother"},{"key":"R10-20240805","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/01.tp.0000225806.80890.5e","article-title":"Three-year observational follow-up of a multicenter, randomized trial on tacrolimus-based therapy with withdrawal of steroids or mycophenolate mofetil after renal transplant.","volume":"82","author":"Pascual","year":"2006","journal-title":"Transplantation"},{"key":"R11-20240805","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1432-2277.2006.00421.x","article-title":"Discontinuation of mycophenolate mofetil from a tacrolimus-based triple regimen 2 months after renal transplantation: a comparative randomized, multicentre study.","volume":"20","author":"Sulowicz","year":"2007","journal-title":"Transpl Int"},{"key":"R12-20240805","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1600-6143.2004.00638.x","article-title":"Minimization of immunosuppressive therapy after renal transplantation: results of a randomized controlled trial.","volume":"5","author":"Vanrenterghem","year":"2005","journal-title":"Am J Transplant"},{"key":"R13-20240805","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1399-0012.2008.00829.x","article-title":"Combination therapy with tacrolimus and mycophenolate mofetil: effects of early and late minimization of mycophenolate mofetil after renal transplant.","volume":"22","author":"Walker","year":"2008","journal-title":"Clin Transplant"},{"key":"R14-20240805","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1097\/01.ASN.0000079616.71891.F5","article-title":"Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation.","volume":"14","author":"Knoll","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"R15-20240805","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1034\/j.1399-0012.2003.00026.x","article-title":"The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation.","volume":"17","author":"Pelletier","year":"2003","journal-title":"Clin Transplant"},{"key":"R16-20240805","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1097\/TP.0000000000002762","article-title":"Optimizing mycophenolic acid exposure in kidney transplant recipients: time for target concentration intervention.","volume":"103","author":"Metz","year":"2019","journal-title":"Transplantation"},{"key":"R17-20240805","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.clinthera.2008.04.014","article-title":"Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients.","volume":"30","author":"Kuypers","year":"2008","journal-title":"Clin Ther"},{"key":"R18-20240805","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/clpt.2014.140","article-title":"Exposure to mycophenolic acid better predicts immunosuppressive efficacy than exposure to calcineurin inhibitors in renal transplant patients.","volume":"96","author":"Daher Abdi","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"R19-20240805","doi-asserted-by":"crossref","first-page":"19379","DOI":"10.1038\/s41598-020-76379-6","article-title":"Initial mycophenolate dose in tacrolimus treated renal transplant recipients, a cohort study comparing leukopaenia, rejection and long-term graft function.","volume":"10","author":"Dave","year":"2020","journal-title":"Sci Rep"},{"key":"R20-20240805","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/nep.13718","article-title":"The impact of age on patient tolerance of mycophenolate following kidney transplantation.","volume":"25","author":"Rennie","year":"2020","journal-title":"Nephrology (Carlton)"},{"key":"R21-20240805","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1111\/j.1600-6143.2009.02726.x","article-title":"Calcineurin inhibitor minimization in the symphony study: observational results 3 years after transplantation.","volume":"9","author":"Ekberg","year":"2009","journal-title":"Am J Transplant"},{"key":"R22-20240805","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate.","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"R23-20240805","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/tri.12554","article-title":"Mycophenolate revisited.","volume":"28","author":"van Gelder","year":"2015","journal-title":"Transpl Int"},{"key":"R24-20240805","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1016\/j.ajt.2023.07.025","article-title":"A rational approach to guide cost-effective de novo donor-specific antibody surveillance with tacrolimus immunosuppression.","volume":"23","author":"Wiebe","year":"2023","journal-title":"Am J Transplant"},{"key":"R25-20240805","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/TP.0000000000000444","article-title":"Frailty, mycophenolate reduction, and graft loss in kidney transplant recipients.","volume":"99","author":"McAdams-DeMarco","year":"2015","journal-title":"Transplantation"},{"key":"R26-20240805","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/tri.12382","article-title":"Do Asian renal transplant patients need another mycophenolate mofetil dose compared with Caucasian or African American patients?","volume":"27","author":"Li","year":"2014","journal-title":"Transpl Int"},{"key":"R27-20240805","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/j.1399-0012.2009.01028.x","article-title":"The impact of reduced immunosuppression on graft outcomes in elderly renal transplant recipients.","volume":"23","author":"Badowski","year":"2009","journal-title":"Clin Transplant"},{"key":"R28-20240805","doi-asserted-by":"crossref","first-page":"e14606","DOI":"10.1111\/ctr.14606","article-title":"Lower versus higher starting tacrolimus dosing in kidney transplant recipients.","volume":"36","author":"Chua","year":"2022","journal-title":"Clin Transplant"},{"key":"R29-20240805","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/j.1600-6143.2011.03464.x","article-title":"Successful ABO-incompatible kidney transplantation with antibody removal and standard immunosuppression.","volume":"11","author":"Flint","year":"2011","journal-title":"Am J Transplant"},{"key":"R30-20240805","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1097\/TP.0b013e3182384b57","article-title":"Nosocomial pneumocystis jirovecii pneumonia: lessons from a cluster in kidney transplant recipients.","volume":"92","author":"Phipps","year":"2011","journal-title":"Transplantation"}],"container-title":["Transplantation Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TXD.0000000000001659","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T04:01:17Z","timestamp":1722830477000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TXD.0000000000001659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,13]]},"references-count":30,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/txd.0000000000001659","relation":{},"ISSN":["2373-8731"],"issn-type":[{"value":"2373-8731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,13]]}}}